These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30121970)

  • 1. Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer.
    Jung K; Park JC; Kang H; Brandes JC
    Epidemiol Health; 2018; 40():e2018040. PubMed ID: 30121970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
    Richards KA; Liou JI; Cryns VL; Downs TM; Abel EJ; Jarrard DF
    J Urol; 2018 Dec; 200(6):1256-1263. PubMed ID: 29940252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years.
    Abdollah F; Sammon JD; Reznor G; Sood A; Schmid M; Klett DE; Sun M; Aizer AA; Choueiri TK; Hu JC; Kim SP; Kibel AS; Nguyen PL; Menon M; Trinh QD
    Eur J Surg Oncol; 2015 Nov; 41(11):1529-39. PubMed ID: 26210655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
    Falchook AD; Basak R; Mohiuddin JJ; Chen RC
    Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
    Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
    BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of acute myocardial infarction after androgen-deprivation therapy for prostate cancer in a Chinese population.
    Teoh JY; Chan SY; Chiu PK; Poon DM; Cheung HY; Hou SS; Ng CF
    BJU Int; 2015 Sep; 116(3):382-7. PubMed ID: 25327618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer.
    Cooperberg MR; Hinotsu S; Namiki M; Carroll PR; Akaza H
    BJU Int; 2016 Jan; 117(1):102-9. PubMed ID: 25238114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer.
    Planas J; Celma A; Placer J; Cuadras M; Regis L; Gasanz C; Trilla E; Salvador C; Lorente D; Morote J
    Scand J Urol; 2016 Dec; 50(6):425-428. PubMed ID: 27628623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.
    Harshman LC; Wang X; Nakabayashi M; Xie W; Valenca L; Werner L; Yu Y; Kantoff AM; Sweeney CJ; Mucci LA; Pomerantz M; Lee GS; Kantoff PW
    JAMA Oncol; 2015 Jul; 1(4):495-504. PubMed ID: 26181260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
    Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
    Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer.
    Sun L; Parikh RB; Hubbard RA; Cashy J; Takvorian SU; Vaughn DJ; Robinson KW; Narayan V; Ky B
    JAMA Netw Open; 2021 Feb; 4(2):e210070. PubMed ID: 33625512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy.
    Grytli HH; Fagerland MW; Fosså SD; Taskén KA; Håheim LL
    Prostate; 2013 Feb; 73(3):250-60. PubMed ID: 22821802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base.
    Amini A; Rusthoven CG; Jones BL; Armstrong H; Raben D; Kavanagh BD
    Urol Oncol; 2016 Apr; 34(4):165.e1-9. PubMed ID: 26699831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
    BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
    Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen deprivation therapy did not increase the risk of Alzheimer's and Parkinson's disease in patients with prostate cancer.
    Chung SD; Lin HC; Tsai MC; Kao LT; Huang CY; Chen KC
    Andrology; 2016 May; 4(3):481-5. PubMed ID: 27062333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.